e-ISSN 2329-0072




Value of Pro-Gastrin Releasing Peptide (Pro-GRP) in patients with lung diseases

Tomasz Bruzdziak, Aleksander Goch, Paweł Ptaszyński, Piotr K Okoński, Gerhard M Oremek

Med Sci Tech 2007; 48(2): RA131-133

ID: 881546

Available online:

Published: 2007-03-18

Introduction: Gastrin-releasing peptide (Pro-GRP), a member of the bombesin family of peptides, has been shown to have mitogenic activity in small cell lung carcinoma (SCLC), and to be produced by SCLC in an autocrine fashion. We investigated the usefulness of serum pro-gastrin releasing peptide (Pro-GRP) as a tumor marker for diagnosis, treatment and monitoring of patients with small-cell lung cancer (SCLC). Material and Methods: This study comprised 80 healthy individuals. Serum samples were also obtained from 80 patients with small-cell carcinoma, 20 with chronic bronchitis, 30 with sarcoidosis and 20 with lung fibrosis. Pro-GRP was measured by an enzyme-linked immunoadsorbent assay. Results: The levels of Pro-GRP in the patients with benign diseases were significantly higher than those in the healthy group. The serum Pro-GRP levels were elevated in SCLC patients. The elevation was significantly higher than this of the benign reference group. Patients suffering from benign disease such as chronic inflammatory resipiratory affections, sarcoidosis and fibrosis served as a reference group. 95% of patients with benign disease had Pro-GRP levels under 87pg/ml This value served as our cut-off. The mean value of Pro-GRP in the SCLC patients 1673pg/ml. Conclusions: These results show that Pro-GRP may be a potential tumor marker for small-cell lung carcinoma. Pro-GRP have a very high sensitivity and good specificity for SCLC detection. (Clin Exp Med Lett 2007; 48(2): 131-133)

Keywords: tumour marker, Pro-GRP, small cell lung cancer (SCLC) adenocarcinoma, non- small-cell lung cancer (NSCLC),, benign lung diseases